Anyone who’s read a Securities and Exchange Commission filing in the U.S. recognizes the risk disclosure section, where biotech and pharma companies list the pitfalls of investing in their shares.
Like an investor-oriented version of the risk disclosures in drug ads, they run the gamut from garden-variety competition to political unrest in farflung markets.
The accounting and advisory firm BDO sifted through those statements to discover just what the top 100 life sciences companies are most worried about these days. And though many of the same challenges have caused a lot of hand-wringing year after year after year, a few of this year’s 25 most anxiety-provoking risks haven’t always been top of mind.
One example—ripped from the headlines, as they say—came in 21st place among the risks cited most often in 2017’s annual reports: Natural disasters, war, conflicts and terrorist attacks. Back in 2013, only 47% of biopharma 10-Ks listed one or more of these as investment risks. This year? A big leap to 81%. Considering the series of enormous storms, earthquakes, terrorist shootings and drive-up attacks, it’s no wonder.
Another headline-making worry: The ability to maintain company infrastructure, including IT security and privacy. The increase there was even more marked, from 46% in 2013 to 89% in 2017. And given that Merck & Co.’s cyber breach happened after most companies filed their annual 10-Ks, that number may well take another jump next year.
But the biggest leap was workforce-related. Labor concerns—including pension costs, rising healthcare costs, immigration and outsourcing—popped up in 78% of the reports examined, up from just 24% in 2013. Healthcare insurance costs for employers have burgeoned over the past five years, of course, and more recently, biopharma companies have flagged immigration shifts as a threat to their ability to attract and keep top scientific (and other) talent.
New to the top of the list? Litigation. Every company examined listed legal proceedings and lawsuits as risks to their operations, up from just 84% in 2013. Take a look at Johnson & Johnson’s legal fight against thousands of claims that its talc products caused ovarian cancer, or AbbVie’s load of lawsuits over the safety of its testosterone drugs. One bellwether testosterone verdict just last week put AbbVie on the hook for $140 million in damages. AbbVie plans to appeal.
Meanwhile, the perennial worries won’t surprise anyone. Competition and marketing challenges figured in at the top in 2017 filings, along with intellectual property protections (or loss thereof) and the success (or not) of current and future drug launches all tied for first place, and they’ve been at or near the top for five years running. And then, of course, there’s regulation, by FDA and other authorities at the state and federal levels.
What’s ahead? FDA and regulation could take the lead, BDO says.
“The top risks cited by the largest 100 U.S. publicly-traded life sciences companies have remained relatively consistent over the last several years, with competitive pressures, intellectual property challenges, and the ability to commercialize and market products all tying for first place this year,” BDO says. “Nevertheless, new leadership steering the Food and Drug Administration (FDA), paired with political and regulatory uncertainty, could impact how those risks evolve.”
By Tracy Staton
Source: Fierce Pharma
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
